Press release
The biopharmaceutical CROs market is projected to be worth USD 67 billion by 2030, claims Roots Analysis
Over past few years, pharmaceutical companies have outsourced various aspects of their R&D and clinical research processes to specialty contract research service providers, in order to remain competitive, flexible, and profitable in the industryRoots Analysis has announced the addition of “Biopharmaceutical CROs Market, 2021-2030,” report to its list of offerings.
Given their numerous advantages, which include high specificity for intended molecular targets, ability to treat a myriad of disease indications, and patient friendly toxicity profiles, the demand for biologics is high and growing. This presents lucrative opportunities for contract research providers that offer services for this rapidly evolving class of pharmacological interventions. In fact, since 2001, over 80 new CROs have been established, offering a wide variety of cost-efficient research services and solutions to biologic developers.
To order this 235+ page report, which features 120+ figures and 110+ tables, please visit this https://www.rootsanalysis.com/reports/biopharmaceutical-cros-market.html
Key Market Insights
More than 160 players claim to offer contract research services to pharmaceutical and biotechnology companies across the world
This segment of the service industry is dominated by start-ups / small companies (2-50 employees) and mid-sized players (51-200 employees), which represent more than 70% of the contemporary CRO landscape. Close to 50% of the stakeholders are based in North America, followed by Europe and the Asia-Pacific region.
More than 45% of companies claim to offer research services for vaccines and cell therapies
On the other hand, close to 40% of CROs claim to have the required capabilities to provide antibody related research services. A number of biopharmaceutical research service providers are now offering services for niche and upcoming classes of biologics, such as Altasciences, Biocon, and Iris Pharma.
Since 2016, more than 70+ partnerships have been inked between CROs and industry stakeholders, worldwide
Interestingly, the maximum number of partnership agreements were inked in 2020, majority of which were acquisitions (34%), followed by clinical trial agreements (28%). It is worth noting that the partnership activity within this domain has increased at a CAGR of 55%, between 2016 and 2021.
Over 30 mergers and acquisitions were established in this domain, during the period 2016-2020
It was observed that majority of the deals were intercontinental (75%), involving participants from different countries. Geographical consolidation and service portfolio expansion were observed to the major key value drivers of M&A activity, followed by service portfolio consolidation (29%) and geographical expansion (26%).
For additional details, please visit
https://www.rootsanalysis.com/reports/biopharmaceutical-cros-market.html
North America and Europe are anticipated to capture 80% share (in terms of service revenues) of the market, by 2030
At present, close to 85% of the total revenues are generated from projects involving antibodies, vaccines and recombinant proteins; this trend is unlikely to change significantly in short to mid-term. It is worth mentioning that the contract research market for biologics in the Latin America is anticipated to grow at a relatively faster rate (14.9%), followed by the services market in MENA (14.5%).
To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis.com/reports/biopharmaceutical-cros-market/request-sample.html
Key Questions Answered
Who are the key players offering contract research services for biopharmaceuticals?
Which kind of business models are commonly adopted by biopharmaceutical companies while outsourcing their R&D and clinical research operations?
What kind of partnership models are commonly adopted by stakeholders in this industry?
What are the key value drivers of the merger and acquisition activity within this domain?
How is the current and future market opportunity likely to be distributed across key market segments?
What are the anticipated future trends within the biopharmaceutical contract research services market?
The USD 67 billion (by 2030) financial opportunity within the biopharmaceutical contract research service providers market has been analyzed across the following segments:
Geography
North America
Europe
Asia-Pacific
MENA
Latin America
Therapeutic Area
Oncological Disorder
Neurological Disorder
Infectious Disorder
Autoimmune Disorder
Cardiovascular Disorder
Respiratory Disorder
Others
Biologics
Antibody
Cell Therapy
Gene Therapy
Vaccine
Recombinant Protein
Others
End-user
Small
Mid-sized
Very large / large
The research includes detailed profiles of key service providers (listed below) engaged in this domain; each profile features an overview of the company, information related to its biologics focused service portfolio, recent developments, and an informed future outlook.
Biocon
Covance
ICON
Medpace
Phamaron
PPD
PRA Health Sciences
Syneos Health
Vimta Labs
WuXi AppTec
For additional details, please visit
https://www.rootsanalysis.com/reports/biopharmaceutical-cros-market.html or email sales@rootsanalysis.com
You may also be interested in the following titles:
1. Top Selling Biologics Market, 2021-2030
2. Cell and Gene Therapy CROs Market (2nd Edition), 2021-2030
3. Biopharmaceutical Contract Manufacturing Market (4th Edition), 2030
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com
Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com
Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The biopharmaceutical CROs market is projected to be worth USD 67 billion by 2030, claims Roots Analysis here
News-ID: 2322752 • Views: …
More Releases from Roots Analysis

Proteomics Market CAGR To Be 7.9% % by 2035, Due To The Growing Adoption of Prot …
According to our latest market report "Proteomics Market" by Type of Offering, Type of Instrument / Technology, Type of Reagent, Type of Proteomics Service, Application Area, End-users, Type of Operation and Geography: Industry Trends and Global Forecasts, Till 2035", the global protein expression market, valued at USD 2.7 billion in 2024, is estimated to reach USD 3.0 billion in 2025 and USD 6.3 billion by 2035, representing a CAGR of…

Industrial Robotics Market to Reach USD 39.03 Billion by 2035, Driven by Rising …
09-04-2025 | Robotics & Automation
Press release from: Roots Analysis
According to Roots Analysis' latest industry report titled "Industrial Robotics Market: Industry Trends and Global Forecasts, till 2035", the global industrial robotics market is projected to grow from USD 17.64 billion in 2024 to USD 18.80 billion in 2025, reaching USD 39.03 billion by 2035 at a CAGR of 7.5% during the forecast period.
To request a quote for this report, visit:
https://www.rootsanalysis.com/industrial-robotics-market/request-quote
Market Overview
Industrial…

Targeted Drug Delivery Device Market Size to reach USD 2,153 million by 2035 | R …
According to our latest market report "Targeted Drug Delivery Device Market" by Type of Device, Target Organ, Type of Therapy Delivered, Route of Administration, Therapeutic Area and Key Geographical Regions: Industry Trends and Global Forecasts, Till 2035", the targeted drug delivery device market size is projected to reach USD 2,153 million by 2035 from USD 427 million in 2026, growing at a CAGR of 19.7% in the forecast period, till…

The Conjugation and Labeling Services Market is projected to grow at a CAGR of 1 …
The complexities associated with conjugation of biomolecules and the need for click-chemistry expertise have prompted the pharmaceutical industry to rely on conjugation and labeling service providers
To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/conjugation-and-labeling-services-market/request-quote.html
Roots Analysis is pleased to announce the publication of its recent study, titled, "Conjugation and Labeling Services Market, 2023-2035"
The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies.…
More Releases for CRO
Global Veterinary CRO & CDMO Market Size & Trends
According to a new market research report published by Global Market Estimates, the global veterinary CRO & CDMO market is expected to grow at a CAGR of 9.1% from 2023 to 2028.
The growing awareness regarding the importance of animal health and welfare has led to increased investments in veterinary pharmaceutical research and development. This awareness is driven by the rising concern for the well-being of pets, livestock, and animals used…
Global Contract Research Organization (CRO) Services Market
According to a new market research report published by Global Market Estimates, the Global Contract Research Organization (CRO) Services Market is expected to grow at a CAGR of 10.2% from 2023 to 2028.
The growth of the contract research organization (CRO) Services Market is fuelled by factors including the rising preference for outsourcing clinical trials, increasing investments in research and development by pharmaceutical and biopharmaceutical companies, the growing complexities in drug…
Contract Research Organization (CRO) Services Market - Efficiency, Expertise, Ex …
Newark, New Castle, USA: The "Contract Research Organization (CRO) Services Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Contract Research Organization (CRO) Services Market: https://www.growthplusreports.com/report/contract-research-organization-cro-services-market/7630
This latest report…
Biopharmaceutical CMO and CRO Market
The Biopharmaceutical CMO and CRO Market crossed US$ 32.25 billion in 2022 and is expected to hit US$ 54.13 billion by 2030, recording a CAGR of 6.5% during the forecast period
Pharmaceutical and biotech companies focus on R&D activities to innovate new molecules and therapeutic platforms to deal with chronic diseases and rare ailments; they also extensively invest in R&D activities to develop various therapeutic applications with strong medical and commercial…
Pracedo Promote Ellie Copp To CRO
Pracedo, a Mashfrog Group company that provides Salesforce consultancy and digital transformation to charities, NGOs, and enterprise customers, promotes Ellie Copp to Chief Revenue Officer.
Pracedo announced Ellie Copp as its new Chief Revenue Officer (CRO). Ellie joined Pracedo in 2019 and most recently held the position of Sales and Marketing Director. As CRO, she will continue to lead the commercial teams by overseeing all revenue-generating activities as Pracedo continues…
Partnership factors in sponsor – CRO relationships
Drugs discovered today can realistically cost upwards of 900 million dollars and around 12 years of development to reach a market. CRO’s have been increasingly used by larger pharma to outsource their clinical research, allowing big pharma to shut down in-house R&D, in practice saving money.
There have been some issues however with the outsourcing of trials to CROs, including serious relationship break down with negative attitudes, failure to communicate…